Cellebrite DI Ltd. (NASDAQ:CLBT) Given Average Recommendation of "Buy" by Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) have earned an average recommendation of "Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $22.43.

A number of research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Cellebrite DI in a report on Friday, June 6th. JPMorgan Chase & Co. reduced their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th.

Cellebrite DI Stock Performance

Shares of CLBT traded up $0.12 during trading hours on Tuesday, hitting $15.32. The company had a trading volume of 1,149,826 shares, compared to its average volume of 1,478,497. The stock has a market capitalization of $3.67 billion, a price-to-earnings ratio of -15.95, a P/E/G ratio of 3.07 and a beta of 1.28. The firm has a fifty day moving average price of $17.29 and a 200-day moving average price of $19.52. Cellebrite DI has a 52-week low of $11.47 and a 52-week high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The firm had revenue of $107.55 million during the quarter, compared to analyst estimates of $109.36 million. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. Cellebrite DI's revenue for the quarter was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.08 earnings per share. Research analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

Institutional investors have recently modified their holdings of the company. Assetmark Inc. bought a new stake in shares of Cellebrite DI during the first quarter worth $33,000. Catalyst Capital Advisors LLC bought a new stake in Cellebrite DI during the first quarter worth about $51,000. Virtus Advisers LLC acquired a new stake in Cellebrite DI in the first quarter valued at $63,000. Gen Wealth Partners Inc acquired a new stake in shares of Cellebrite DI during the 4th quarter worth about $85,000. Finally, NewEdge Advisors LLC lifted its holdings in Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.